TapImmune President & CEO, Peter Hoang, will be participating in two conferences in the upcoming weeks.
TapImmune President & CEO, Peter Hoang, to present at Biotech Showcase next week.
TapImmune Announces Enrollment of First Patient in Phase 2 Clinical Trial for Treating Triple-Negative Breast Cancer Funded by U.S. Department of Defense
“We remain grateful to the U.S. Department of Defense and Mayo Clinic for enabling TapImmune to gain invaluable clinical safety and efficacy insight for TPIV200 under this grant,” said TapImmune President and CEO Peter Hoang.
You can now view the presentation from last Thursday’s Virtual Investor Conference call.
Dr. Kenney will continue to manage the Company’s ongoing and planned clinical programs for its novel, multi-epitope, T-cell vaccine candidates.
TapImmune President and CEO, Peter Hoang, to host live webcast on December 7th at 10:45am.
TapImmune President and CEO, Peter Hoang, will be presenting at the 29th Annual Piper Jaffray Healthcare Conference.
Chairman and Strategic Advisor Glynn Wilson, Ph.D., and Senior Director of Molecular Biology & Virology Robert Florkiewicz, Ph.D., will give an oral presentation titled, “Increasing the potency of DNA-based immunotherapies using PolyStart™ peptide expression system,” at the World Vaccine & Immunotherapy Congress West Coast, held Thursday, November 30 – December 1, 2017, at the Loews Coronado Bay Resort in San Diego, CA.
Please join us for TapImmune’s third quarter 2017 corporate and clinical update today, Novmber 15th at 4:30pm ET.
TapImmune Completes Patient Enrollment Ahead of Schedule in Phase 2 Cancer Vaccine Study for Treating Triple-Negative Breast Cancer
Triple-negative breast cancer is a difficult-to-treat condition, but one where patients may stand to benefit significantly from immunotherapies that are effective at continually fighting off disease progression long after initial cancer therapy. As a multi-peptide therapeutic vaccine, TPIV200 is designed to do just that.